Education
About Us
Working with TipRanks
Follow Us
Ibio Inc (IBIO)
NASDAQ:IBIO
IBIO Stock Chart & Stats
$2.49
-$0.02(-0.74%)
At close: 4:00 PM EST
$2.49
-$0.02(-0.74%)
Day’s Range― - ―
52-Week Range$0.56 - $5.60
Previous CloseN/A
Volume55.53K
Average Volume (3M)1.09M
Market Cap
$84.63M
Enterprise Value$12.46M
Total Cash (Recent Filing)$52.70M
Total Debt (Recent Filing)$2.45M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
May 18, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding34,543,560
10 Day Avg. Volume1,079,065
30 Day Avg. Volume1,094,305
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue41.54
Enterprise Value/Gross Profit-54.18
Enterprise Value/Ebitda-0.58
Forecast
1Y Price Target
$5.67Price Target Upside127.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$200.00K
Bulls Say, Bears Say
Bulls Say
Differentiated Antibody ApproachAnalyst highlights IBIO-610 as the only antibody-based activin E program with potential for deeper target suppression, co-formulation with GLP-1 therapies, and fully scalable manufacturing, which could create scarcity value.
Platform And Pipeline OptionalityAnalyst emphasizes the company's AI-driven antibody discovery platform and multiple preclinical candidates, which increase the chance of additional assets and upside beyond the lead obesity program.
Preclinical Efficacy EvidenceAnalyst notes non-human primate data showing IBIO-610 reduced visceral and total fat while preserving lean mass, supporting activin E as a viable obesity target and strengthening the therapy's clinical rationale.
Bears Say
Cash Runway And Financing RiskAnalyst warns that limited cash relative to development spending could necessitate additional financing, increasing dilution risk and potentially pressuring program timelines.
Market Sentiment And Short InterestAnalyst points to meaningful short interest and a substantial fully diluted share base, which could amplify downward pressure on the stock and heighten investor dilution concerns.
Preclinical-stage UncertaintyAnalyst notes that programs remain preclinical, so stock performance may depend on competitor clinical readouts and uncertainty persists until internal human data are available.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.56 and its highest was $5.60 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $84.63M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is May 18, 2026 which is in 65 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on Feb 10, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.05.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 34,543,560 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -2.643%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (127.71% Upside)
$5.67 (127.71% Upside)
Blogger Sentiment
Bullish
IBIO Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-55.13%
12-Months-Change
Fundamentals
Return on Equity
-71.26%
Trailing 12-Months
Asset Growth
196.78%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$5.67
▲(127.71% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
0.73%
Insiders
0.84% Mutual Funds
14.31% Other Institutional Investors
82.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---